

TNFRSF10B

Recombinant Human TRAIL-R2 / CD262 (His Tag)

Catalog No.	CRH490A-His CRH490B-His	Quantity:	100 µg 200 µg
Alternate Names:	Tumor necrosis factor receptor superfamily member 10B, Death receptor 5, TNF-related apoptosis-inducing ligand receptor 2, TRAIL receptor 2, TRAIL-R2, CD262		
Description:	TNF-related apoptosis-inducing ligand receptor 2 (TRAIL-R2), is a member of the TNF-receptor superfamily, and contains an intracellular death domain. This receptor can be activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF1/TRAIL/APO-2L), and transduces an apoptosis signal. Studies with FADD-deficient mice suggested that FADD, a death domain containing adaptor protein, is required for the apoptosis mediated by this protein. TRAIL-R2 was purified independently as the only receptor for TRAIL detectable on the surface of two different human cell lines that undergo apoptosis upon stimulation with TRAIL. TRAIL-R2 contains two extracellular cysteine-rich repeats, typical for TNF receptor (TNFR) family members, and a cytoplasmic death domain. TRAIL-R2 mediates apoptosis via the intracellular adaptor molecule FADD/MORT1. TRAIL receptors can signal both death and gene transcription, functions reminiscent of those of TNFR1 and TRAMP, two other members of the death receptor family. Defects in TRAIL-R2 may be a cause of head and neck squamous cell carcinomas (HNSCC) also known as squamous cell carcinoma of the head and neck.		
UniProt ID:	O14763		
Accession Number:	NP_003833		
Protein Construction:	A DNA sequence encoding the human TNFRSF10B extracellular domain (Met 1-Glu 182) was expressed, fused with a polyhistidine tag at the C-terminus.		
Source:	HEK293 Cells		
Formulation:	Lyophilized from sterile PBS, pH 7.4 Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.		
Molecular Weight:	The recombinant human TNFRSF10B consists of 138 amino acids and has a predicted molecular mass of 15.8 kDa. As a result of glycosylation, the apparent molecular mass of rhTNFRSF10B is approximately 20-22 kDa in SDS-PAGE under reducing conditions.		
Purity:	> 95 % as determined by SDS-PAGE		
Endotoxin Level:	< 1.0 EU per µg protein as determined by the LAL method.		
Biological Activity:	Measured by its binding ability in a functional ELISA. Immobilized human TNFRSF10B at 10 µg/ml (100 µl/well) can bind biotinylated TNFSF10 with a linear range of 0.625-20 ng/ml.		
Predicted N-terminal:	Ile 56		
Reconstitution:	Centrifuge vial prior to opening. Add sterile distilled water to a concentration of 0.1 mg/mL and gently pipette the solution up and down the sides of the vial. DO NOT VORTEX. Allow several minutes for complete reconstitution.		



Storage & Stability: Stable for up to 1 year from date of receipt at -20°C to -80°C
After reconstitution, store working aliquots at -20°C to -80°C.
Avoid repeated freeze-thaw cycles.

NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.